Study guide

32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy

Philippine Physician Licensure Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: PLE Structure, Eligibility & Study Strategy

1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan

2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle

2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction

3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems

3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments

4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems

4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation

5 Chapter 5: Physiology IV: Neurophysiology & Special Senses

5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses

6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death

6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death

7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning

7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws

8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics

8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics

9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics

9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock

10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection

10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology

11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology

11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura

12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology

12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors

13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry

13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism

14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry

14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure

15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back

15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes

16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin

16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands

17 Chapter 17: Anatomy III: Head, Neck & Histology

17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology

18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections

18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis

19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections

19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning

20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections

20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases

21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections

21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis

22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding

22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage

23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems

23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception

24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception

24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria

25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues

25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents

26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections

26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections

27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders

27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning

28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders

28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child

29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider

29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036

30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine

30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine

31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer

31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health

32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics

32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections

33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics

33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy

34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics

34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis

35 Chapter 35: Surgery I: Basic Surgical Principles

35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety

36 Chapter 36: Surgery II: Abdomen, Breast & Hernia

36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma

37 Chapter 37: Surgery III: Surgical Specialties

37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)

38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine

38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome

39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine

39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS

40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry

40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)

32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy

Key Takeaways Explain This Topic AI

ACE inhibitors cause dry cough and angioedema through bradykinin; both ACE inhibitors and ARBs cause hyperkalemia and acute kidney injury in bilateral renal artery stenosis and are contraindicated in pregnancy.

In a hypertensive emergency, lower mean arterial pressure by no more than about 25% in the first hour with titratable IV drugs such as nicardipine, labetalol or nitroprusside; aortic dissection needs faster lowering with beta-blockade first.

Norepinephrine is the first-line vasopressor in septic shock, epinephrine is first-line in anaphylaxis, and dobutamine supports contractility in cardiogenic shock.

HFrEF quadruple therapy (ARNI or ACEi/ARB, an evidence-based beta-blocker, an MRA and an SGLT2 inhibitor) lowers mortality; digoxin and loop diuretics relieve symptoms only.

Statins inhibit HMG-CoA reductase and are first-line for lowering LDL; myopathy risk rises with fibrates (especially gemfibrozil) and CYP3A4 inhibitors.

Last updated: October 2026

Why this area matters

The TOS asks for drug treatment of:

  • hypertension and hypertensive emergencies ;
  • hypotension and shock ;
  • heart failure ;

dyslipidemia .

Hypertension is one of the most common reasons for consultation in the Philippines and a leading risk factor for stroke and heart disease. Guidelines emphasize lifestyle change plus combination therapy to reach blood pressure targets, usually below 130/80 mmHg for most adults at high risk.

  • Antihypertensive Pharmacology & Diuretic Regimens
  • Renin-Angiotensin-Aldosterone System (RAAS) Blockers

ACE Inhibitors (Captopril, Enalapril, Lisinopril, Ramipril) :

Mechanism : Inhibit Angiotensin-Converting Enzyme (ACE / Kininase II), preventing the conversion of Angiotensin I to the potent vasoconstrictor Angiotensin II. Simultaneously inhibit the enzymatic breakdown of bradykinin and substance P.

Hemodynamic & Renal Effects : Decreases systemic vascular resistance (afterload reduction) without reflex tachycardia. Selectively dilates the efferent arteriole of the renal glomerulus, lowering intraglomerular capillary hydrostatic pressure; this slows long-term renal microalbuminuria and diabetic nephropathy, but causes a transient, anticipated initial dip in GFR ( < 30 % < 30\% < 30% rise in serum creatinine is acceptable).

Adverse Effects :

Persistent Dry Cough ( 5 – 20 % 5\text{--}20\% 5 – 20% ): Mediated by pulmonary accumulation of bradykinin and substance P.

Angioedema ( 0.1 – 0.5 % 0.1\text{--}0.5\% 0.1 – 0.5% ): Life-threatening, non-pitting swelling of lips, tongue, pharynx, and larynx mediated by bradykinin accumulation (not histamine-mediated; epinephrine/antihistamines are ineffective; requires airway protection and C1-esterase inhibitor or icatibant if available).

Hyperkalemia : Due to reduced aldosterone-mediated potassium excretion.

Acute Kidney Injury in Bilateral Renal Artery Stenosis : In bilateral stenosis, glomerular filtration is maintained by Angiotensin II-mediated efferent arteriolar constriction; ACE inhibitors abolish this autoregulation, causing acute prerenal azotemia.

Teratogenicity : Category D; causes fetal renal dysgenesis, oligohydramnios, pulmonary hypoplasia, and neonatal anuria (Potter sequence).

Angiotensin Receptor Blockers (ARBs: Losartan, Valsartan, Candesartan, Telmisartan) :

Mechanism : Competitively block Angiotensin II Type 1 ( A T 1 AT_1 A T 1 ​ ) receptors, preventing Angiotensin II-induced vasoconstriction and aldosterone secretion.

Distinction from ACEi : ARBs do not inhibit kininase II and do not increase bradykinin levels. Therefore, ARBs do not cause dry cough and carry a vastly lower incidence of angioedema. Indicated as first-line alternatives for patients who cannot tolerate ACE inhibitors due to cough. Share identical risks of hyperkalemia, acute kidney injury in bilateral renal artery stenosis, and fetal teratogenicity.

Calcium Channel Blockers (CCBs)

Block voltage-gated L-type calcium channels ( C a v 1.2 Cav1.2 C a v 1.2 ) in vascular smooth muscle and cardiac myocytes, inhibiting intracellular calcium influx and excitation-contraction coupling.

Dihydropyridines (Amlodipine, Nifedipine, Nicardipine, Felodipine) :

Tissue Selectivity : High vascular selectivity (vascular smooth muscle ≫ \gg ≫ myocardium).

Clinical Effects : Potent peripheral arteriolar vasodilation; minimal direct effect on cardiac conduction or contractility. Short-acting nifedipine can trigger dangerous reflex sympathetic tachycardia (avoided in acute coronary syndromes).

Adverse Effects : Dependent peripheral ankle edema (caused by preferential precapillary arteriolar dilation increasing capillary hydrostatic pressure, not fluid retention; unresponsive to loop diuretics), lightheadedness, facial flushing, and gingival hyperplasia.

Non-Dihydropyridines (Verapamil, Diltiazem) :

Tissue Selectivity : Cardiac myocytes and nodal tissue ≥ \ge ≥ vascular smooth muscle. Verapamil is cardioselective (heart > > > vessels); Diltiazem has intermediate balanced selectivity.

Clinical Effects : Suppress SA node automaticity ( negative chronotropy ), slow AV node conduction velocity ( negative dromotropy ), and depress myocardial contractility ( negative inotropy ). Used for rate control in atrial fibrillation and supraventricular tachycardias.

Adverse Effects & Contraindications : Constipation (most prominent with verapamil due to colonic smooth muscle relaxation), bradycardia, heart block, and worsening of heart failure. Strictly contraindicated in patients with Heart Failure with Reduced Ejection Fraction (HFrEF) and second- or third-degree AV block.

Diuretic Classes: Thiazide, Loop & Potassium-Sparing

Diuretic Class Primary Nephron Site & Transporter Electrolyte & Metabolic Profile Key Clinical Indications Distinguishing Toxicities & Board Pearls

Thiazides (Hydrochlorothiazide, Chlorthalidone) Early Distal Convoluted Tubule: inhibits N a + / C l − Na^+/Cl^- N a + / C l − cotransporter (NCCT) HyperGLUC : HyperGlycemia, HyperLipidemia, HyperUricemia, HyperCalcemia. Hypokalemic metabolic alkalosis, Hyponatremia Essential hypertension (Chlorthalidone preferred), recurrent idiopathic calcium nephrolithiasis, nephrogenic diabetes insipidus Less effective when eGFR < 30 mL/min/1.73m 2 \text{eGFR} < 30\text{ mL/min/1.73m}^2 eGFR < 30 mL/min/1.73m 2 (metolazone and chlorthalidone retain some effect). Increases renal calcium reabsorption (beneficial in osteoporotic hypertension)

Loop Diuretics (Furosemide, Bumetanide, Torsemide, Ethacrynic Acid) Thick Ascending Limb of Henle: inhibits apical N a + / K + / 2 C l − Na^+/K^+/2Cl^- N a + / K + /2 C l − cotransporter (NKCC2) Hypokalemic hypochloremic metabolic alkalosis, Hypocalcemia (loops lose calcium), Hypomagnesemia, Hyperuricemia Acute pulmonary edema, decompensated heart failure, cirrhosis with ascites, acute hypercalcemia Ototoxicity (tinnitus, sensorineural deafness; ethacrynic acid highest, worsened by aminoglycosides). Sulfa allergy cross-reactivity ( Ethacrynic acid is the non-sulfa loop alternative)

Potassium-Sparing / MRAs (Spironolactone, Eplerenone, Amiloride, Triamterene) Late Distal Tubule & Cortical Collecting Duct: blocks aldosterone receptor or ENaC channels Hyperkalemia , metabolic acidosis (normal anion gap type 4 RTA) HFrEF quadruple therapy, primary hyperaldosteronism (Conn syndrome), resistant hypertension Spironolactone : causes painful gynecomastia, impotence, and menstrual irregularities via androgen receptor blockade. Eplerenone : selective MRA with minimal endocrine effects

Heart Failure Guideline-Directed Medical Therapy (GDMT)

Modern management of Heart Failure with Reduced Ejection Fraction ( L V E F ≤ 40 % LVEF \le 40\% L V EF ≤ 40% ) centers on foundational Quadruple Therapy , which reverses adverse neurohormonal cardiac remodeling and drastically reduces cardiovascular hospitalization and all-cause mortality.

The Four Pillars of HFrEF Quadruple Therapy

Angiotensin Receptor-Neprilysin Inhibitor (ARNI: Sacubitril-Valsartan) :

Mechanism : Sacubitril is a prodrug whose active metabolite inhibits neprilysin (neutral endopeptidase), preventing the enzymatic degradation of beneficial endogenous natriuretic peptides (ANP, BNP), bradykinin, and adrenomedullin. Valsartan concurrently blocks the A T 1 AT_1 A T 1 ​ receptor, counteracting angiotensin II.

The 36-Hour Washout Rule : Because both ACE and neprilysin degrade bradykinin, co-administering an ACE inhibitor with an ARNI leads to massive, synergistic bradykinin accumulation and catastrophic, fatal angioedema . Clinical guidelines strictly mandate a 36-hour washout period between the last dose of an ACE inhibitor and the initiation of sacubitril-valsartan. (No washout is required when transitioning from an ARB to an ARNI).

Evidence-Based Beta-Blockers (Carvedilol, Metoprolol Succinate, Bisoprolol) :

Only three beta-blockers possess proven mortality benefit in chronic HFrEF: Carvedilol (non-selective beta plus α 1 \alpha_1 α 1 ​ blocker), Metoprolol succinate (extended-release β 1 \beta_1 β 1 ​ blocker; not short-acting metoprolol tartrate), and Bisoprolol .

Initiated at low starting doses in clinically stable, euvolemic patients and slowly titrated upward to target doses. Blunt chronic sympathetic hyperactivation, prevent arrhythmia-induced sudden cardiac death, and reverse ventricular remodeling.

Mineralocorticoid Receptor Antagonists (MRAs: Spironolactone or Eplerenone) :

Inhibit aldosterone binding in renal collecting ducts and myocardial interstitium, suppressing cardiac collagen synthesis, myocardial fibrosis, and vascular remodeling (RALES, EPHESUS trials). Serum potassium and renal function must be monitored.

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors (Dapagliflozin or Empagliflozin) :

Promotes osmotic diuresis, decreases ventricular preload and afterload, improves myocardial energetics, and preserves renal function. Proven to reduce cardiovascular mortality and heart failure hospitalizations in HFrEF regardless of whether the patient has diabetes mellitus (DAPA-HF, EMPEROR-Reduced trials).

Digoxin: Inotropy, Parasympathomimetic Action & Toxicity

Mechanism of Inotropy : Reversibly inhibits the myocardial sarcolemmal N a + / K + Na^+/K^+ N a + / K + ATPase pump. This causes intracellular [ N a + ] [Na^+] [ N a + ] to rise, reducing the inward sodium electrochemical gradient that drives the N a + / C a 2 + Na^+/Ca^{2+} N a + / C a 2 + exchanger (NCX) . Consequently, calcium extrusion is diminished, and intracellular [ C a 2 + ] [Ca^{2+}] [ C a 2 + ] accumulates within the sarcoplasmic reticulum. Upon subsequent depolarization, augmented calcium release drives enhanced cross-bridge formation, yielding positive inotropy .

Electrophysiological Effects : Stimulates central vagal nuclei, increasing parasympathetic tone at the AV node. This prolongs AV nodal refractoriness and slows ventricular response in atrial fibrillation ( negative dromotropy ).

Mortality Reality : Digoxin improves clinical symptoms, exercise tolerance, and reduces heart failure hospitalizations, but does not reduce all-cause mortality (DIG trial).

Digoxin Toxicity Profile :

Narrow Therapeutic Window : Target level 0.5 – 0.9 ng/mL 0.5\text{--}0.9\text{ ng/mL} 0.5 – 0.9 ng/mL ; toxicity frequently manifests at levels > 2.0 ng/mL > 2.0\text{ ng/mL} > 2.0 ng/mL .

Precipitating Factors : Hypokalemia (potassium competes with digoxin for the N a + / K + Na^+/K^+ N a + / K + ATPase binding site; when potassium is low, digoxin binding and toxicity are markedly increased), hypomagnesemia, hypercalcemia, and renal failure.

Clinical Manifestations : Gastrointestinal distress (anorexia, nausea, vomiting, abdominal pain), central neuropsychiatric disturbances (lethargy, confusion, weakness), and unique ocular changes ( xanthopsia —yellow-green halos around lights, blurred vision).

Cardiac Arrhythmias : Can cause virtually any arrhythmia: frequent premature ventricular contractions (PVCs, most common), paroxysmal atrial tachycardia with AV block, junctional escape rhythms, and fatal bidirectional ventricular tachycardia .

Management of Severe Toxicity : Discontinue digoxin; normalize serum potassium and magnesium; administer Digoxin-specific antibody fragments (DigiFab) for life-threatening arrhythmias, severe hyperkalemia ( K + > 5.0 mEq/L K^+ > 5.0\text{ mEq/L} K + > 5.0 mEq/L in acute ingestion), or massive overdose; temporary cardiac pacing or atropine for severe refractory bradycardia.

Choosing antihypertensives

First-line classes: ACE inhibitor or ARB, calcium channel blocker, and thiazide or thiazide-like diuretic. Combinations (often single-pill) are used when BP is far above target.

Compelling indications:

  • diabetes with albuminuria or CKD: ACE inhibitor or ARB ;
  • heart failure: ACE inhibitor or ARNI, beta-blocker and MRA;
  • after MI: beta-blocker and ACE inhibitor;
  • pregnancy : methyldopa, labetalol or nifedipine (never ACE inhibitors or ARBs);
  • BPH: an alpha-blocker as an add-on;

isolated systolic hypertension in older adults: a CCB or thiazide.

Combinations to avoid: never combine an ACE inhibitor with an ARB (more renal failure and hyperkalemia). Beta-blockers are not first-line for uncomplicated hypertension.

Monitoring: check creatinine and potassium 1 to 2 weeks after starting or increasing an ACE inhibitor, ARB or MRA. A rise in creatinine of up to 30% is acceptable.

Hypertensive emergencies

Definition: severely raised BP (often 180/120 mmHg or more) with acute target-organ damage : encephalopathy, stroke, ACS, acute pulmonary edema, aortic dissection, acute kidney injury or eclampsia.

Initial target: lower mean arterial pressure by no more than about 25% in the first hour , then toward 160/100 over the next 2 to 6 hours. Too-rapid lowering causes cerebral, coronary or renal ischemia.

Exceptions:

aortic dissection : systolic below 120 mmHg within 20 minutes, with beta-blockade first (esmolol or labetalol), then a vasodilator;

acute ischemic stroke : lower only if BP is above 185/110 before thrombolysis, or above 220/120 otherwise;

eclampsia and preeclampsia : labetalol, hydralazine or nifedipine plus magnesium.

IV drugs:

  • nicardipine or clevidipine (dihydropyridine CCBs);
  • labetalol ;
  • esmolol ;
  • nitroglycerin , for ACS and pulmonary edema;

sodium nitroprusside , a potent arteriovenous dilator. Its cyanide and thiocyanate toxicity with prolonged use or renal failure causes metabolic acidosis and confusion, and is treated with hydroxocobalamin or sodium thiosulfate.

Hypertensive urgency (high BP without organ damage): resume or adjust oral therapy and reduce BP over days. Avoid sublingual nifedipine.

Hypotension and shock

Shock type Hemodynamics Drugs

Septic (distributive) Low SVR, high or normal cardiac output Fluids, then norepinephrine first-line; add vasopressin ; epinephrine; hydrocortisone if refractory

Anaphylactic Vasodilation, capillary leak, bronchospasm IM epinephrine 0.5 mg (adult; 0.01 mg/kg in children) , fluids, then antihistamines and steroids

Cardiogenic Low cardiac output, high SVR and wedge pressure Dobutamine for contractility; norepinephrine if hypotensive; revascularization; avoid excess fluids

Hypovolemic Low preload Fluids and blood ; vasopressors are not a substitute

Neurogenic Low SVR with bradycardia Fluids, vasopressors (phenylephrine or norepinephrine), atropine for bradycardia

Adverse effects of vasopressors: tachyarrhythmias, limb and gut ischemia, and tissue necrosis on extravasation , treated with local phentolamine .

Infusions: give them through a central line when possible.

Dopamine causes more arrhythmias than norepinephrine in septic shock.

Lipid-lowering therapy

Drug Mechanism Main effects Adverse effects

Statins (atorvastatin, rosuvastatin, simvastatin) Inhibit HMG-CoA reductase , which upregulates hepatic LDL receptors Lower LDL the most; reduce cardiovascular events Myalgia, myopathy, rhabdomyolysis ; raised transaminases; slightly more diabetes; contraindicated in pregnancy

Ezetimibe Blocks intestinal cholesterol absorption (NPC1L1) Adds about 20% LDL lowering to statins Well tolerated

PCSK9 inhibitors (evolocumab, alirocumab), inclisiran Prevent LDL-receptor degradation Large LDL reduction Injection-site reactions; cost

Fibrates (fenofibrate, gemfibrozil) Activate PPAR-alpha, which increases lipoprotein lipase Lower triglycerides most Myopathy with statins (especially gemfibrozil) , gallstones

Bile acid sequestrants (cholestyramine) Bind bile acids in the gut Lower LDL GI upset; raise triglycerides; bind other drugs

  • Niacin Reduces VLDL secretion Raises HDL Flushing (prevented by aspirin), hyperglycemia, hyperuricemia
  • Omega-3 fatty acids Reduce VLDL production Lower triglycerides Fishy taste

Statin intensity: high-intensity statins are indicated for established ASCVD, LDL of 190 mg/dL or more, and diabetic or high-risk patients.

Monitoring: check the lipid profile 4 to 12 weeks after starting, and check CK only if there are muscle symptoms.

Interactions: CYP3A4 inhibitors (macrolides, azoles, grapefruit) raise simvastatin and atorvastatin levels and myopathy risk.

Severe hypertriglyceridemia (above 500 to 1,000 mg/dL) is treated with a fibrate and diet to prevent pancreatitis .

Loading diagram... Heart Failure GDMT Quadruple Therapy and Neurohormonal Blockade